Skip to main content

INSM

Stock

INSM

Stock
Health Care
Biotechnology

Performance overview

INSM Price
Price Chart

Forward-looking statistics

Beta
1.47
Risk
75.54%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Company info

SectorHealth Care
IndustryBiotechnology
Employees845
Market cap$9.3B

Fundamentals

Enterprise value$18.4B
Revenue$381.0M
Revenue per employee
Profit margin-265.93%
Debt to equity1316.96

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.93
Dividend per share
Revenue per share$2.21
Avg trading volume (30 day)$514M
Avg trading volume (10 day)$697M
Put-call ratio

Macro factor sensitivity

Growth-1.7
Credit+7.2
Liquidity+1.4
Inflation-3.9
Commodities-1.5
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-23.12
Price to sales48.76
P/E Ratio-23.12
Enterprise Value to Revenue48.39
Price to book179.45

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

CNBC Television (July 7, 2025)
Is Insmed Stock Overvalued After The 45% Jump?

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?

Forbes (June 16, 2025)
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension.

Benzinga (June 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free